Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile
Obesity · 2024
DOI: 10.1002/oby.24019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity, 2024. Verfasst von Yuval Cohen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Corbus Pharmaceuticals Holdings Inc., Norwood, Massachusetts, USA. Hauptthemen laut MEDLINE: Rimonabant, United States Food and Drug Administration, Anti-Obesity Agents, Suicide. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Targeting the cannabinoid type 1 receptor (CB1) is a clinically validated antiobesity therapeutic approach. The only such drug approved, rimonabant, was launched in 2006 in Europe but subsequently rejected by the US Food and Drug Administration (FDA) in 2007. The FDA cited the increased risk of suicidality in its opposition to rimonabant's approval, leading to the drug's eventual worldwide withdrawal and the abandonment of this class of therapeutics. Seventeen years later, a new class of CB1‐targeting drugs is emerging, but the impact of the 2007 FDA decision remains a formidable obstacle to its clinical development. We revisit the suicidality data presented by the FDA in light of the evolution of suicidality assessment and cross‐reference this with the data in the subsequently published clinical trials. We conclude that the publicly available data do not support the FDA's conclusion that the use of rimonabant was associated with an increase in the risk of suicidality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Corbus Pharmaceuticals Holdings Inc., Norwood, Massachusetts, USA.
ORCID-Profile: Marshall Morningstar
Zitieren
APA
Cohen, Y., Kolodziej, A., & Morningstar, M. (2024). Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile. Obesity. https://doi.org/10.1002/oby.24019
Vancouver
Cohen Y, Kolodziej A, Morningstar M. Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile. Obesity. 2024. doi:10.1002/oby.24019
BibTeX
@article{Cohen2024,
author = {Cohen, Yuval and Kolodziej, Andrew and Morningstar, Marshall},
title = {Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile},
journal = {Obesity},
year = {2024},
doi = {10.1002/oby.24019}
}
EUVIMED